Labcorp Holdings Inc. has announced its financial results for the second quarter of 2025, reporting an increase in revenue to $3.53 billion compared to $3.22 billion in the same period in 2024. The company's diluted earnings per share $(EPS)$ rose to $2.84 from $2.43, and the adjusted EPS increased to $4.35 from $3.94 year-over-year. Labcorp has updated its full-year guidance, raising its enterprise revenue growth range to 7.5% to 8.6%, with the midpoint increased by 70 basis points. The adjusted EPS guidance has been narrowed to a range of $16.05 to $16.50, with the midpoint raised by $0.23. The free cash flow forecast is now between $1.13 billion to $1.28 billion, with the midpoint increased by $25 million. The company has broadened its partnerships with hospitals, health systems, and regional/local labs, enhancing access to comprehensive testing and laboratory services. Additionally, Labcorp has introduced several new tests in high-growth specialty areas, including oncology.